Combination of a STAT3 Inhibitor and an mTOR Inhibitor Against a Temozolomide-resistant Glioblastoma Cell LineHaruo Miyata, Yasuto Akiyama|Cancer Genomics & Proteomics|2017Cited by 41
YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell lineYasuto Akiyama, Ken Yamaguchi|Oncology Reports|2014Cited by 36
<i>In Vivo</i>Antitumor Activity of the PD-1/PD-L1 Inhibitor SCL-1 in Various Mouse Tumor ModelsTadashi Ashizawa, Yasuto Akiyama|In Vivo|2024Cited by 1
Impact of the PD-1/PD-L1 inhibitor SCL-1 on MDA-MB231 tumor growth in a humanized MHC-double knockout NOG mouse modelTomoatsu Ikeya, Yasuto Akiyama|Scientific Reports|2025Cited by 1